Benefits Pro44m
Will Wegovy help that worker lose weight?
New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.
ENDPOINTS NEWS24m
Met­sera’s long-act­ing GLP-1 looks com­pet­i­tive in Phase 2 obe­si­ty study
Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for monthly dosing and no titration requirement.